A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Recruiting · Phase 1 · NCT06297590
Conditions: Alzheimer Disease
At a glance
- Research payments reported, 2025
- $3.5M
- U.S. investigators named
- 7
- Sites paid
- 9
- Planned or actual enrollment
- 56
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3954068 (drug), Placebo (drug), Flortaucipir F18 (drug)
- Dates
- Started 2024-08-15; completion 2028-07
- Results posted
- Not yet
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive up to 4 doses of either LY3954068 or placebo administered into the spinal fluid. Participants may have the opportunity to join an optional bridging period to a separate potential study where participants …
From ClinicalTrials.gov, last updated 2026-10-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.5M in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brandon Lenox, D.O. Anesthesiology · Maitland, FL
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Jeffrey A. Norton, M.D. Pain Medicine · Lawrence, MA
- Shruti M. Raja, MD Physical Medicine & Rehabilitation (PM&R) · Durham, NC
- Sanjiv K. Sharma, M.D. Internal Medicine · Toms River, NJ
- Arun Singh, M.D. Emergency Medicine · Toms River, NJ
- Steven E. Arnold, MD Psychiatry · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- K2 Medical Research LLC $2.8M
- Massachusetts General Hospital, MA $240,581
- Charter Research LLC $181,962
- Advanced Memory Research Institute of Nj PC $125,932
- Cenexel Iresearch LLC $108,136
- Duke University $72,849
- $10,900
- Advocare Berlin Medical Associates $5,015
- Dana Farber PArtners Cancer Care Inc $2,179
- Brigham and Women's Hospital, MA $1,778
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.